JPMorgan Positive on Rocket Pharmaceuticals (RCKT), 'we see current share levels as an attractive entry point to capture longer-term pipeline potential'
Tweet Send to a Friend
JPMorgan analyst Eric Joseph reiterated an Overweight rating on Rocket Pharmaceuticals (NASDAQ: RCKT).The analyst comments "Coming away from the topline ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
